Literature DB >> 11879381

Selective blockade of N-type calcium channels by levetiracetam.

E A Lukyanetz1, V M Shkryl, P G Kostyuk.   

Abstract

PURPOSE: We investigated the effect of the new antiepileptic drug (AED) levetiracetam (LEV) on different types of high-voltage-activated (HVA) Ca2+ channels in freshly isolated CA1 hippocampal neurons of rats.
METHODS: Patch-clamp recordings of HVA Ca2+ channel activity were obtained from isolated hippocampal CA1 neurons. LEV was applied by gravity flow from a pipette placed near the cell, and solution changes were made by electromicrovalves. Ca2+ channel blockers were used for separation of the channel subtypes.
RESULTS: The currents were measured in controls and after application of 1-200 microM LEV. LEV irreversibly inhibited the HVA calcium current by approximately 18% on the average. With a prepulse stimulation protocol, which can eliminate direct inhibition of Ca2+ channels by G proteins, we found that G proteins were not involved in the pathways underlying the LEV inhibitory effect. This suggested that the inhibitory effect arises from a direct action of LEV on the channel molecule. The blocking mechanism of LEV was not related to changes in steady-state activation or inactivation of Ca2+ channels. LEV also did not influence the rundown of the HVA Ca2+ current during experimental protocols lasting approximately 10 min. Finally, LEV at the highest concentration used (200 microM) did not influence the activity of L-, P- or Q-type Ca2+ channels in CA1 neurons, while selectively influencing the activity of N-type calcium channels. The maximal effect on these channels separated from other channel types was approximately 37%.
CONCLUSIONS: Our results provide evidence that LEV selectively inhibits N-type Ca2+ channels of CA1 pyramidal hippocampal neurons. These data suggest the existence of a subtype of N-type channels sensitive to LEV, which might be involved in the molecular basis of its antiepileptic action.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11879381     DOI: 10.1046/j.1528-1157.2002.24501.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  56 in total

1.  Levetiracetam as preventive treatment in adults with migraine: an up-to-date systematic review and quantitative meta-analysis.

Authors:  Georgia Tsaousi; Chryssa Pourzitaki; Spyridon Siafis; Athanassios Kyrgidis; Vasilios Grosomanidis; Dimitrios Kouvelas; Georgios Papazisis
Journal:  Eur J Clin Pharmacol       Date:  2019-11-25       Impact factor: 2.953

2.  Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited.

Authors:  Rainer Surges; Kirill E Volynski; Matthew C Walker
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

3.  Recent and future advances in the treatment of status epilepticus.

Authors:  Felix Rosenow; Susanne Knake
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

Review 4.  GABAA receptors, anesthetics and anticonvulsants in brain development.

Authors:  Oliver Henschel; Keith E Gipson; Angelique Bordey
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-04       Impact factor: 4.388

5.  Two cases of cluster headache effectively treated with levetiracetam.

Authors:  Antonio Palermo; Giuseppe Giglia; Giuseppe Cosentino; Vincenzo Raieli; Filippo Brighina; Brigida Fierro
Journal:  Funct Neurol       Date:  2013 Jan-Mar

6.  Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112).

Authors:  David F McComsey; Virginia L Smith-Swintosky; Michael H Parker; Douglas E Brenneman; Ewa Malatynska; H Steve White; Brian D Klein; Karen S Wilcox; Michael E Milewski; Mark Herb; Michael F A Finley; Yi Liu; Mary Lou Lubin; Ning Qin; Allen B Reitz; Bruce E Maryanoff
Journal:  J Med Chem       Date:  2013-11-11       Impact factor: 7.446

7.  Region-specific changes in gene expression in rat brain after chronic treatment with levetiracetam or phenytoin.

Authors:  Bjørnar Hassel; Erik Taubøll; Renee Shaw; Leif Gjerstad; Ray Dingledine
Journal:  Epilepsia       Date:  2010-09       Impact factor: 5.864

Review 8.  Effects of antiepileptic drugs on antioxidant and oxidant molecular pathways: focus on trace elements.

Authors:  Mustafa Nazıroğlu; Vedat Ali Yürekli
Journal:  Cell Mol Neurobiol       Date:  2013-04-14       Impact factor: 5.046

9.  Levetiracetam inhibits Na+-dependent Cl-/HCO3- exchange of adult hippocampal CA3 neurons from guinea-pigs.

Authors:  Tobias Leniger; Jan Thöne; Udo Bonnet; Andreas Hufnagel; Dieter Bingmann; Martin Wiemann
Journal:  Br J Pharmacol       Date:  2004-07-12       Impact factor: 8.739

10.  Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures.

Authors:  Carol M Ulloa; Allen Towfigh; Joseph Safdieh
Journal:  Neuropsychiatr Dis Treat       Date:  2009-09-15       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.